Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Benjamin Burnett
WF
Benjamin Burnett
Wall Street Analyst
★★★☆☆
#1278
on 13Foresight · ranked by our own returns
61%
Success Rate
+10.5%
Average Return
23 of 38 calls profitable · +0.7% vs benchmark
📈 Across the calls we could measure, roughly 61% of Benjamin Burnett's ratings turned a profit when each position was held for 1 year — averaging +10.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

84 Buy 18 Hold 0 Sell
Benjamin's Stock Coverage 35 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
TECX
Tectonic Therapeutic
Jun 12, 2026 BUY Strong Buy
+88.0% avg upside
24 analysts
$101.00
236.54% Upside
·
AXSM
Axsome Therapeutics
Jun 10, 2026 BUY Strong Buy
-10.5% avg upside
28 analysts
$255.00
1.86% Upside
+2.3%
ALKS
Alkermes
Jun 08, 2026 BUY Strong Buy
-17.5% avg upside
34 analysts
$44.00
2.16% Downside
+6.8%
LQDA
Liquidia Technologies
Jun 04, 2026 BUY Strong Buy
-28.2% avg upside
15 analysts
$62.00
12.76% Downside
+8.6%
INSM
Insmed
Jun 04, 2026 BUY Strong Buy
+82.1% avg upside
36 analysts
$160.00
66.93% Upside
-6.2%
MNKD
MannKind
Jun 02, 2026 BUY Buy
+78.6% avg upside
22 analysts
$11.00
179.28% Upside
·
XENE
Xenon
Jun 01, 2026 BUY Strong Buy
+19.0% avg upside
28 analysts
$69.00
30.36% Upside
-1.9%
PRAX
Praxis Precision Medicines
Jun 01, 2026 HOLD Strong Buy
+92.1% avg upside
24 analysts
$323.00
14.48% Upside
-19.4%
SVRA
Savara
May 22, 2026 BUY Strong Buy
+58.2% avg upside
17 analysts
$9.00
63.72% Upside
·
WVE
Wave Life Sciences
May 20, 2026 BUY Strong Buy
+261.8% avg upside
28 analysts
$14.00
127.32% Upside
-0.5%
KROS
Keros Therapeutics
May 15, 2026 BUY Strong Buy
+139.8% avg upside
21 analysts
$20.00
87.81% Upside
+0.0%
AMPH
Amphastar Pharmaceuticals
May 14, 2026 HOLD Hold
+41.2% avg upside
11 analysts
$19.00
0.94% Upside
·
UTHR
United Therapeutics
May 07, 2026 BUY Buy
-19.0% avg upside
26 analysts
$738.00
37.52% Upside
-3.1%
RARE
Ultragenyx Pharmaceutical
May 06, 2026 BUY Strong Buy
+142.0% avg upside
36 analysts
$47.00
71.28% Upside
-10.9%
RAPP
Rapport Therapeutics, Inc.
Apr 22, 2026 BUY Strong Buy
+46.2% avg upside
12 analysts
$46.00
23.27% Upside
+0.2%
CNTA
Centessa Pharmaceuticals
Apr 20, 2026 HOLD Buy
-14.4% avg upside
19 analysts
$42.00
4.94% Upside
+0.9%
PTCT
PTC Therapeutics
Apr 13, 2026 BUY Buy
-1.4% avg upside
29 analysts
$86.00
8.95% Upside
+11.5%
RVMD
Revolution Medicines
Apr 01, 2025 BUY Strong Buy
-12.2% avg upside
32 analysts
$64.00
60.74% Downside
+193.4%
CABA
Cabaletta Bio
Mar 31, 2025 BUY Strong Buy
+390.0% avg upside
16 analysts
$13.00
357.79% Upside
+94.9%
PGEN
Precigen
Mar 20, 2025 BUY Buy
+404.8% avg upside
11 analysts
$7.00
45.23% Upside
+82.2%
ALLO
Allogene Therapeutics
Mar 17, 2025 HOLD Strong Buy
+662.8% avg upside
28 analysts
$4.00
100.08% Upside
+22.7%
IOVA
Iovance Biotherapeutics
Mar 17, 2025 BUY Strong Buy
+225.4% avg upside
24 analysts
$18.00
360.33% Upside
+4.0%
ATRA
Atara Biotherapeutics
Mar 11, 2025 HOLD Buy
+79.8% avg upside
18 analysts
$3.00
70.27% Downside
-5.8%
FATE
Fate Therapeutics
Mar 06, 2025 HOLD Buy
+492.3% avg upside
31 analysts
$3.00
43.53% Upside
+27.9%
IRON
Disc Medicine
Mar 03, 2025 BUY Strong Buy
+20.3% avg upside
21 analysts
$92.00
29.87% Upside
+18.5%
JSPR
Jasper Therapeutics
Mar 02, 2025 BUY Strong Buy
+6345.3% avg upside
17 analysts
$80.00
17560.06% Upside
-75.8%
CRSP
Crispr Therapeutics AG
Feb 13, 2025 HOLD Buy
+39.7% avg upside
41 analysts
$49.00
9.42% Downside
+22.0%
IDYA
IDEAYA Biosciences
Nov 06, 2024 BUY Strong Buy
+55.3% avg upside
29 analysts
$64.00
104.90% Upside
-1.8%
EFTR
eFFECTOR Therapeutics
Apr 19, 2024 BUY Strong Buy
+66249899.9% avg upside
5 analysts
$10.00
4999899.91% Upside
-100.0%
DTIL
Precision BioSciences
Aug 16, 2023 BUY Strong Buy
+250.1% avg upside
12 analysts
$42.00
516.74% Upside
-43.9%
SGMO
Sangamo Therapeutics
Aug 10, 2023 HOLD Buy
+5843.7% avg upside
16 analysts
$3.60
1963.03% Upside
-5.6%
NKTR
Nektar Therapeutics
Mar 02, 2023 HOLD Strong Buy
+16.6% avg upside
25 analysts
$3.00
95.10% Downside
-49.4%
NGNE
Neurogene
Nov 15, 2022 HOLD Buy
+55.9% avg upside
23 analysts
$4.50
85.75% Downside
+62.4%
GNCAQ
Genocea Biosciences
Apr 29, 2022 HOLD Strong Buy
+573999900.0% avg upside
10 analysts
$0.16
15999900.04% Upside
·
BEAM
Beam Therapeutics
Feb 28, 2022 BUY Strong Buy
+51.4% avg upside
25 analysts
$120.00
251.51% Upside
-48.6%
🔒 30 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Benjamin Burnett — Frequently Asked Questions
How accurate are Benjamin Burnett's stock ratings?
Based on the calls 13Foresight could measure, about 61% of Benjamin's ratings were profitable over a one-year hold, with an average return of +10.5% per rating, or +0.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Benjamin ranked on 13Foresight?
Benjamin Burnett is currently ranked #1278 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Benjamin cover?
Benjamin most recently has ratings on TECX, AXSM, ALKS, LQDA, INSM, MNKD, XENE, PRAX, SVRA, WVE, KROS, AMPH and 23 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.